Although not specifically under development for breast cancer, heparanase inhibitors have entered Phase II clinical trials, with the sulfated oligosaccharide PI-88 demonstrating activity in hepatocellular carcinoma [22]. The gene discussed is HPSE; the disease is breast cancer.